Gout
Documents
Febuxostat
Brand(s)
- Generics of Uloric (see formulary OFIs)
Dosage Form/Strength
- 80 mg
Updated
- September 29, 2022
Indications for Treatment
To lower serum uric acid levels, where recommended according to clinical guidelines, in patients with gout or hyperuricemia meeting at least one of the following:
- Patient has experienced an inadequate response to maximum tolerated doses of allopurinol; OR
- Patient has experienced a hypersensitivity reaction to allopurinol; OR
- Patient has documentation of an absolute contraindication to allopurinol.
Patients who have experienced severe intolerances to allopurinol not meeting the above criteria will be considered on a case-by-case basis.
Duration of Approval
- Initial Approval: 1 year
- Renewals:
- Considered for patients where there is objective evidence of clinical benefit from the use of febuxostat.
- Renewal Approval Period: 5 years
Renewal Criteria
- Objective Evidence of Clinical Benefit:
- Demonstrated improvement in gout symptoms or serum uric acid levels.
